• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Glen Spielmans, PhD

Articles by Glen Spielmans, PhD

Research Update

L-Methylfolate May Offer Modest Boost to Antidepressants

April 14, 2023
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Glen Spielmans, PhD. Dr. Spielmans has no financial relationships with companies related to this material.

A meta-analysis of this FDA-cleared supplement.


Read More
EXPERT Q&A

Duty to Warn? Debating Antidepressant Suicidality

October 30, 2020
Martha J. Ignaszewski, MD and Glen Spielmans, PhD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Martha J. Ignaszewski, MD
Fellow, University of California, San Francisco      





Glen Spielmans, PhD
Professor of Psychology, Metropolitan State University, St. Paul, MN


Dr. Ignaszewski and Dr. Spielmans have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For 16 years, since the FDA black box warning about suicidality with antidepressants, our community has been quoting data that downplays this concern. We were wrong. We were deceived. Antidepressants can be lifesaving, but there really is a duty to warn. Drs. Martha Ignazewski and Glen Speilmans talk with us about what went on and how to talk about it with our families.
Read More

Mood Stabilizer Plus Antidepressant May Protect Against Mania

September 1, 2014
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Most of you would hesitate to put a patient with bipolar I on antidepressants without adding a mood stabilizer, in order to prevent a switch to mania. If this is your clinical practice, you are following the recommendations of the APA consensus guidelines for the treatment of bipolar depression. But the hard data to support the danger of switching is surprisingly weak.
Read More

CBT Moderately Effective in Improving Quality of Life for Anxiety Disorders

September 1, 2014
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Cognitive behavioral therapy (CBT) has been shown to be effective in reducing the symptoms of anxiety disorders. But there’s not a lot of information about whether it improves patients’ quality of life (QoL), even though one would think improvement in QoL is inherent when anxiety is reduced.
Read More

Overview of the FDA Drug Approval Process

July 1, 2014
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
After a psychiatric drug is approved by the Food and Drug Administration (FDA), a marketing juggernaut often follows, trying to convince us that the newly approved drug offers substantial benefits for treating a mental disorder. But how does the FDA determine whether to approve a drug? What follows is a breakdown of the process.
Read More
RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?
Read More

Is Low Dose Lithium Effective in Bipolar Disorder?

February 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
Although it remains one of our oldest and most effective drugs, lithium has become less popular for the treatment of bipolar disorder in the last two decades.
Read More

Drugs Acting on Glutamate

February 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
You’re probably hearing a lot of talk about glutamate receptors as a new target for psychiatric therapeutics. As the most abundant excitatory neurotransmitter in the brain, glutamate is thought to play a role in many psychiatric conditions.
Read More

Some Popular Antipsychotics May Not be Effective in Patients over 40

January 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
  Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects.
Read More

Marijuana May Hurt Cognitive Function, Worse with Heavier Use

October 1, 2012
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Does marijuana affect cognitive function? There seems to be no shortage of opinions on this question, but no prospective, longitudinal study has ever been published. Until now, that is.
Read More
Previous 1 2 3 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.